Library – Page 10 – Myeloma Academy

Biology and genetics

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. Botta C et al. Leukemia. 2017 Nov 21. doi: 10.1038/leu.2017.336. [Epub ahead of print]. Protein arginine methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in multiple myeloma. Gullà A et al.Leukemia. 2017 Nov 21. doi: 10.1038/leu.2017.334. [Epub ahead of print]. Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences…

November 27, 2017Journal, Library, Management of MyelomaBy sarahfleming

IMWG Consensus of second primary malignancies in myeloma

This paper, written by a panel of experts from the International Myeloma Working Group (IMWG), reviews the available data on second primary malignancies in myeloma, and provides recommendations for treatment and management.

November 2, 2017Clinical guidelines & position statements, Complications, IMWG, LibraryBy sarahfleming

IMWG Consensus criteria for response and minimal residual disease in myeloma

This paper, produced by an expert panel of the International Myeloma Working Group (IMWG) reviews the assessment of disease response and endpoints for clinical trials, and provides updated response categories of minimal residual disease negativity.

Read abstract

November 2, 2017Clinical guidelines & position statements, Imaging & Analysis, IMWG, LibraryBy sarahfleming

IMWG Consensus statement on the treatment of myeloma patients with high-risk cytogenetics

This paper, produced by the International Myeloma Working Group (IMWG), provides an updated definition of high-risk myeloma based on cytogenetics and provides recommendations for the optimum treatment for this group of myeloma patients.

November 2, 2017Clinical guidelines & position statements, IMWG, Library, Management & TreatmentBy sarahfleming

IMWG Recommendations for the management of relapsed myeloma

This paper, written by the International Myeloma Working Group (IMWG), reviews the current evidence, and provides recommendations for the management of patients with relapsed myeloma.

Read abstract

November 2, 2017Clinical guidelines & position statements, IMWG, Library, Management & TreatmentBy sarahfleming

IMWG Recommendations for the diagnosis and management of myeloma-related renal impairment

This paper by the International Myeloma Working Group, reviews the available evidence and provides recommendations for the management of myeloma-related kidney disease

November 2, 2017Clinical guidelines & position statements, Complications, IMWG, LibraryBy sarahfleming

EMN Guidelines for the management of myeloma-related conditions

These guidelines, produced by an expert panel on behalf of the European Myeloma Network (EMN), provide recommendations for the management of the most common complications of myeloma, including bone and kidney disease.

November 2, 2017Clinical guidelines & position statements, Complications, European Myeloma Network, LibraryBy sarahfleming

Supportive treatments

Advances in the Treatment of Paraproteinemic Neuropathy. Nobile-Orazio E et al. Curr Treat Options Neurol. 2017 Oct 16;19(12):43. doi: 10.1007/s11940-017-0479-9. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study. Sens F et al. Am J Nephrol. 2017 Oct 10;46(5):355-363. doi: 10.1159/000481461. [Epub ahead of print]. Interbody distraction and vertebral body reconstruction with polymethylmethacrylate for the treatment of pathological…

October 26, 2017Journal, Library, Myeloma Prognosis & OutcomesBy sarahfleming

Related conditions

Elevation of Plasmin-α2-plasmin Inhibitor Complex Predicts the Diagnosis of Systemic AL Amyloidosis in Patients with Monoclonal Protein. Ishiguro K et al. Intern Med. 2017 Oct 11. doi: 10.2169/internalmedicine.8999-17. [Epub ahead of print]. Metachronous solitary plasmacytoma. Khosa R et al. BMJ Case Rep. 2017 Oct 19;2017. pii: bcr-2017-221780. doi: 10.1136/bcr-2017-221780. Intratubular amyloid in light chain cast nephropathy is a risk factor for…

October 26, 2017Journal, LibraryBy sarahfleming

General

A Comparative Assessment of Quality of Life in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model. Martino M et al. Biol Blood Marrow Transplant. 2017 Oct 12. pii: S1083-8791(17)30764-4. doi: 10.1016/j.bbmt.2017.09.021. [Epub ahead of print]. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the…

October 26, 2017Journal, LibraryBy sarahfleming

Category Archives: Library